

increase in the plasma concentration of human tissue factor, a decrease in platelets, a decrease in fibrinogen, an increase in the concentration of soluble fibrin monomer complex, and an increase in the concentration of thrombin-antithrombin III complex.

a2  
Covered

7. (Once Amended) A method of generating the animal according to claim 1, wherein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene is implanted to non-human animals and then an animal having a persistent hypercoagulable state is selected.

8. (Once Amended) A method of screening an anti-thrombotic agent which method comprises using the animal according to claim 1.

a3

12. (Once Amended) The preventive or therapeutic agent according to claim 9 wherein said antibody is an altered antibody.

13. (Once Amended) The preventive or therapeutic agent according to claim 9 wherein said antibody is an altered antibody.

14. (Once Amended) The preventive or therapeutic agent according to claim 9 wherein said altered antibody is a chimereic antibody or a humanized antibody.

a4

16. (Once Amended) The preventive or therapeutic agent according to claim 9 wherein said antibody is a modified antibody.

21. (Once Amended) The preventive or therapeutic agent according to claim 18 wherein said antibody is a recombinant antibody.

a5

22. (Once Amended) The preventive or therapeutic agent according to claim 18 wherein said antibody is an altered antibody.

23. (Once Amended) The preventive or therapeutic agent according to claim 18 wherein said antibody is an altered antibody.

24. (Once Amended) The preventive or therapeutic agent according to claim 18 wherein said altered antibody is a chimereic antibody or a humanized antibody.

25. (Once Amended) The preventive or therapeutic agent according to claim 18 wherein said antibody is a modified antibody.

26. (Once Amended) The preventive or therapeutic agent according to claim 27 wherein said antibody is a recombinant antibody.

27. (Once Amended) The preventive or therapeutic agent according to claim 27 wherein said antibody is an altered antibody.

28. (Once Amended) The preventive or therapeutic agent according to claim 27 wherein said altered antibody is a chimeric antibody or a humanized antibody.

29. (Once Amended) The preventive or therapeutic agent according to claim 27 wherein said antibody is a modified antibody.

30. (Once Amended) The preventive or therapeutic agent according to claim 36 wherein said antibody is a recombinant antibody.

31. (Once Amended) The preventive or therapeutic agent according to claim 36 wherein said antibody is an altered antibody.

32. (Once Amended) The preventive or therapeutic agent according to claim 36 wherein said altered antibody is a chimeric antibody or a humanized antibody.

33. (Once Amended) The preventive or therapeutic agent according to claim 36 wherein said antibody is a modified antibody.

34. The preventive or therapeutic agent according to claim 45 wherein said antibody is a recombinant antibody.

aw 49. (Once Amended) The preventive or therapeutic agent according to claim 45 wherein said antibody is an altered antibody.

50. (Once Amended) The preventive or therapeutic agent according to claim 45 wherein said altered antibody is a chimeric antibody or a humanized antibody.

all 52. (Once Amended) The preventive or therapeutic agent according to claim 43 wherein said antibody is a modified antibody.

#### REMARKS

Applicants respectfully request that the foregoing amendments be made prior to examination of the present application. The amendments are made to correct multiple dependencies and do not change the scope of the invention.

Respectfully submitted,

Date March 29, 2002

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407

Facsimile: (202) 672-5399

By 

Harold C. Wegner  
Attorney for Applicants  
Registration No. 25,258